Protagenic Debt To Assets from 2010 to 2024

PTIXW Stock  USD 0.01  0  34.03%   
Protagenic Therapeutics Debt To Assets yearly trend continues to be fairly stable with very little volatility. Debt To Assets will likely drop to 0.04 in 2024. During the period from 2010 to 2024, Protagenic Therapeutics Debt To Assets regression line of quarterly data had mean square error of  0.88 and geometric mean of  0.39. View All Fundamentals
 
Debt To Assets  
First Reported
2010-12-31
Previous Quarter
0.0385
Current Value
0.0366
Quarterly Volatility
1.29796902
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 137.6 K or Selling General Administrative of 1.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

Latest Protagenic Therapeutics' Debt To Assets Growth Pattern

Below is the plot of the Debt To Assets of Protagenic Therapeutics over the last few years. It is Protagenic Therapeutics' Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Debt To Assets10 Years Trend
Slightly volatile
   Debt To Assets   
       Timeline  

Protagenic Debt To Assets Regression Statistics

Arithmetic Mean1.08
Geometric Mean0.39
Coefficient Of Variation120.40
Mean Deviation1.10
Median0.33
Standard Deviation1.30
Sample Variance1.68
Range3.8434
R-Value(0.72)
Mean Square Error0.88
R-Squared0.51
Significance0
Slope(0.21)
Total Sum of Squares23.59

Protagenic Debt To Assets History

2024 0.0366
2023 0.0385
2022 0.0428
2021 0.0288
2020 1.56
2015 0.33
2014 3.87

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Debt To Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Assets 0.04  0.04 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.